The objective of this study was to investigate the association between human leukocyte antigens (HLA) phenotypes and cardiovascular remodelling, as expressed by left ventricular mass (LVM) and carotid intima-media thickness (IMT), in hypertensives. We examined 153 subjects with arterial hypertension and 61 normotensive controls living in the greater Athens area. The population was classified into three groups and specifically group I (normotensives), group II with Grade 1 hypertension and group III with Grade 2 or 3 hypertension. HLA class I and class II antigens were studied by microlymphocytotoxic technique. Carotid IMT and LVM were determined by ultrasonography. The prevalence of HLA DQ7 in the hypertensive cohort was 27.4% that was significantly smaller than the 52.5% among the controls (P ¼ 0.002). The HLA DR11 was found in 24.0% of the hypertensives and in 52.5% of the controls (Po0.001). Group III hypertensives with HLA DR11 exhibited significantly higher LVM/h in comparison to the hypertensives without this HLA (199.0 7 28.8 vs 171.2+44.1g/m, P ¼ 0.009). This association was not present in groups I and II. Similarly, group III hypertensives with HLA DQ7 were characterized by higher IMT in comparison to those without this HLA (0.94 7 0.19 vs 0.83 7 0.23 mm, P ¼ 0.048). HLA DR17 was associated with higher IMT in both groups II and III (1.00 7 0.19 vs 0.82 7 0.19 mm, P ¼ 0.046 and 1.01 7 0.23 vs 0.84 7 0.22 mm, P ¼ 0.049, respectively) but not in group I. In conclusion, certain HLA phenotypes may be related to the levels of arterial blood pressure. Moreover, it seems that these HLA phenotypes may identify subjects with arterial hypertension that are more prone to develop cardiovascular hypertrophy.
Introduction
There is strong evidence of a causal relation between blood pressure and absolute left ventricular mass (LVM). However, the degree of such hypertrophy, especially in subjects with mildly elevated arterial pressure, is not uniform and may range from normal ventricular mass to severe hypertrophy. 1 In the Framingham Heart Study, only 10% of the variation in LVM among subjects is accounted for by differences in systolic blood pressure (SBP) averaged over 30 years. 2 Similarly, average blood pressure obtained during awaking hours from hypertensive subjects accounts for 10-25% of LVM variation. 3 In normotensive persons, enhanced augmentation of SBP by reflected waves, a process associated with the ageing of the arterial tree, elevates wall stress and is associated with increased LVM. 4 Additionally, common carotid artery intima-media thickness (IMT) has been associated with arterial hypertension and the prevalence of cardiovascular diseases. 5, 6 The poor correlation between the levels of blood pressure and the magnitude of cardiovascular hypertrophy has been attributed to the fact that office blood pressure does not accurately reflect the haemodynamic load. Better correlation has been reported between LVM and ambulatory blood pressure monitoring (ABPM). 7 However, cases exhibiting an inconsistency between arterial hypertension and the degree of hypertrophy are frequent. The polymorphism of angiotensinogen and angiotensin-converting enzyme genes has been associated with cardiovascular hypertrophy, although this association has been disputed. 8, 9 Nevertheless, it has been postulated that other genotypic and or phenotypic characteristics may be implicated in the observed variability of cardiovascular hypertrophy in subjects with arterial hypertension. 10 Human leukocyte antigens (HLA) is the designation for antigens that are products of a complex of genes at several closely linked loci collectively called the major histocompatibility complex (MHC), located on chromosome 6. The genes are allelic and thus a number of different forms of each gene are found in the population. The MHC is a major determinant of the immune response. It is considered to play a significant role in the pathophysiology of atherosclerosis. Furthermore, certain HLA have been associated with arterial hypertension and its complications. In a North Chinese hypertensive population, an increased prevalence of HLA DR1 antigen has been reported, while the HLA Cw4 antigen has been observed to be significantly more frequent among Spanish subjects with malignant hypertension. 11, 12 A previous report from our centre has demonstrated that HLA DQ7, DR11, DR13 and DR17 are associated with target organ damage in a Greek hypertensive population. 13 However, these preliminary results could not clarify whether HLA phenotypes have a detrimental effect on target organs directly or through arterial hypertension.
The aim of the present study is to investigate a putative association of an intermediate phenotypic characteristic, such as the HLA antigens, with arterial hypertension and to explore the relation of HLA phenotypes with cardiovascular remodelling, as expressed by LVM and carotid IMT.
Subjects and methods

Study population
The study population was recruited from individuals who attended the Blood Pressure Clinic of our department during the period February 1996 to June 2000. This clinic also serves to stratify cardiovascular risk in nonmotensive subjects that attend departments of our hospital. A total of 214 participants, 106 males and 108 females were finally enrolled in the study. They had not received any antihypertensive medication and were free of cardiovascular events. The subjects of the studied cohort were unrelated to each other and originated from the ethnically homogeneous Greek population and lived in the greater Athens area. Written informed consent was obtained from all subjects in order to participate in the study. At the screening visit, the medical history of each participant was recorded using a standard questionnaire for cardiovascular diseases in order to define the overall cardiovascular risk profile. A thorough clinical examination was performed for each patient, followed by laboratory investigations; complete lipoprotein analysis was included using enzymatic methods after a 12-h fasting period.
Classification of the studied population
Office measurements of systolic and diastolic blood pressure were performed manually with a mercury sphygmomanometer. Three consecutive sets of readings, at least 1 week apart, were obtained. The diagnosis of hypertension was based on mean casual SBP exceeding 140 mmHg and/or diastolic blood pressure (DBP) exceeding 90 mmHg.
In all, 153 subjects, 81 males and 72 females, mean age 50.2 7 12.1 years, were hypertensives, and 61 participants, 32 males and 29 females, mean age 49.1 7 13.2 years, were normotensives and comprised the control group (group I). In order to clarify the role of HLA phenotypes in cardiovascular hypertrophy, according to the levels of blood pressure, we further classified the hypertensive population into two subgroups (groups II and III). Group II consisted of 64 subjects, 35 males and 29 females, mean age 49.1 7 13.2 years, with Grade 1 hypertension according to the WHO classification (140-159/90-99 mmHg).
14 Group III comprised 89 hypertensives, 46 males and 43 females, mean age 51.0 7 11.3 years, with Grade 2 or 3 arterial hypertension (X160/100 mmHg).
HLA typing
The currently identified HLA class I (-A, -B, -Cw) and class II (-DR, -DQ) antigens were studied by a classical two-step microlymphocytotoxic technique in peripheral blood T and B lymphocytes, separated by immunomagnetic beads and by molecular techniques (PCR-SSO, PSR-SSP), using commercial kits (INNO-LiPA, Dynal).
15,16
Carotid ultrasonography
Carotid B-mode real-time ultrasound examinations were performed by two trained physicians who were unaware of the patients' grouping. We used an ATL 3000 HDI apparatus with a 7.0 MHz linear phased array transducer. The patients were examined in the supine position with slight extension of the neck. Measurements of the IMT were performed in the right and left common carotid arteries, 15-20 mm proximal to the dilatation of the carotid bulb in an end-diastolic 'frozen' and magnified B-mode image. For methological reasons, measurements were taken from the far wall only between the first lumenintima interface and the second echogenic line signifying the media-adventitia interface. Three measurements in contiguous sites, 1 mm apart, were performed in each segment in order to calculate the mean IMT for each carotid artery. The highest IMT value of both carotid arteries was calculated and used in the analysis. Wall thickness assessments were never made on a discrete plaque or when two adjacent measurements differed by more than 50%.
In this case, only the contralateral common carotid artery IMT was used for further analysis.
Echocardiography
All echocardiograms were performed by two experienced cardiologists who were unaware of the patients' condition. Two-dimensional targeted Mmode echocardiograms were recorded. Left ventricular internal diameters, posterior wall and septal thickness were measured according to the recommendations of the American Society of Echocardiography. 17 A second set of measurements was also obtained according to the Penn convention criteria to calculate LVM. Each measurement was performed three times and the average values were used to calculate the LVM according to the formula of Devereux and Reicheck:
18 LVM(g) ¼ 1.04{ (LVDD+  VST+PWT) 3 À(LVDD) 3 }À13.6, where LVDD stands for left ventricular diastolic diameter, VST for ventricular septum thickness, and PWT for posterior wall thickness. LVM was normalized by dividing it by the individuals height (h) in meters (LVM/h). Patients with valvular stenosis or more than mild valvular regurgitation on Doppler echocardiography were excluded from the study.
Statistical analysis
The results are presented as mean 7 1 s.d. All statistical analyses were carried out by using SPSS for Windows (Release 10.0). Comparisons between the three groups in terms of continuous characteristics were tested by one-way analysis of variance (ANOVA), followed by the Student-Newman-Keuls (S-N-K) post hoc comparison. The prevalence of HLA phenotypes was compared by the w 2 test for contingency tables. Corrections for type I errors were made by the use of a modified Bonferroni's procedure. According to this procedure, the level of significance a is adjusted to a ¼ a*/k, where a* is the probability of committing at least one type I error in a number of k tests. 19 In addition, since the procedure tends to be rather conservative, a more generous value, up to 0.20, is often used. Comparisons of participants defined by the presence or absence of certain HLA phenotypes in terms of IMT and LVM/h were tested by means of ANOVA using as covariates those variables which were indicated as significant by the above-mentioned levels. Variables with skewed, nonsymmetrical distributions were analysed after transformation to logarithmic scale that resulted in a normal distribution of the respective data. The independent influence of demographic and other serum characteristics, hypertension, and each of the HLA antigens (those which showed significant associations in univariate analyses) on IMT or LVM/h was studied by means of multiple linear regression (applied in backward stepwise fashion) with the latter as dependent variables, in the whole population and groups I, II and III, separately. The independent variables for hypertension represented categories as follows: two dummy variables representing the contrasts of the two hypertensive groups from controls. Similarly, the HLA antigens were all dichotomous variables (presence/absence) and they were used as such.
Results
The analysis of the descriptive characteristics of both hypertensive and normotensive subjects revealed significantly higher body mass index (BMI), serum cholesterol, triglyceride and LDL-cholesterol levels in the hypertensive population ( Table 1) 
Regarding the HLA, in the final analysis we tested a total of 27 HLA antigens that exhibited a frequency of at least 5% in our hypertensive and/or normotensive population. HLA antigens with lower frequency were not further analysed in order to avoid significant associations that could be because of chance. Then were no significant differences in the prevalence of HLA phenotypes among hypertensives and normotensives except for HLA DQ7, DR11 and DR16. Will respect to HLA DQ7, the prevalence among the hypertensive cohort was 27.4% that was significantly smaller than among the controls (52.5%) (w 2 ¼ 12.079, P ¼ 0.002). The prevalence of HLA DR11 among the hypertensives and controls were 24.0 and 52.5% (w 2 ¼ 15.659, Po0.001). Similarly, HLA DR16 exhibited smaller prevalence in hypertensives than in controls (12.8 vs 29.4%, w 2 ¼ 6.087, P ¼ 0.048). However, after adjusting the level of significance (a ¼ 0.007) for 27 multiple tests, only the tests for the HLA phenotypes DQ7 and DR11 were statistically significant. The result for the HLA DR16 can be regarded as type I error. (Figure 1 ).
IMT according to grouping classification and HLA typing
Group I exhibited significantly lower IMT (0.75 7 0.16 mm) in comparison to groups II and III (0.84 7 0.19 mm, P ¼ 0.012 and 0.87 7 0.22 mm, P ¼ 0.003, respectively). However, the mean IMT did not differ significantly between the latter two groups (P ¼ NS). The preliminary analysis showed that only the following four HLA phenotypes could be associated with the IMT: DQ7, DR11 DR13 and DR17. In the final analysis only two HLA reached statistical significance. Specifically, the presence of HLA DQ7 was associated with higher IMT in group III (0.94 7 0.18 vs 0.83 7 0.23 mm, P ¼ 0.048). In contrast, groups I and II did not exhibit significant differences in IMT according to the presence or absence of this HLA (0.76 7 0.16 mm vs 0.73 7 0.16 mm, P ¼ NS and 0.85 7 0.17 vs 0.82 7 0.20 mm, P ¼ NS, respectively). HLA DR17 was associated with higher IMT in both groups II and III (1.00 7 0.19 vs 0.81 7 0.19 mm, P ¼ 0.046 and 1.01 7 0.23 vs 0.85 7 0.22 mm, P ¼ 0.049, respectively), but not in group I (0.78 7 0.17 vs 0.75 7 0.16 mm, P ¼ NS) (Figure 2 ). Its prevalence did not differ significantly among the normotensive and the hypertensive subjects (22.9 vs 18.3%, respectively, P ¼ NS). The association of HLA DQ7 and DR17 with IMT was independent of the blood pressure levels and the serum lipid concentrations.
In a multivariate analysis, the associations of the specific HLA antigens with LVM/h and carotid IMT were proved to be independent of age, gender, serum cholesterol levels, the presence of diabetes mellitus and the smoking habits. The coexistence of the aforementioned HLA antigens and their associations with carotid IMT and LVM/h could not be further analysed because of the small size of the hypertensive sample.
Discussion
The present study suggests that there may be a reverse association of specific HLA phenotypes with the presence of arterial hypertension. Specifically, HLA DQ7 and DR11 were found with significantly lower frequency among Greek hypertensives in comparison to subjects with normal blood pressure. Based on these results, we initially hypothesized that certain HLA phenotypes may exert a 'protective' effect on the development of arterial hypertension. These phenotypes are inherited by the Mendelian model and thus they may mark subjects whose genetic elements, although not yet determined, intervene in the pathogenesis of essential hypertension. Previous studies have shown a relation between HLA phenotypes and arterial blood pressure as well as malignant hypertension. 11, 12 It is known that race and ethnicity play a pivotal role in the prevalence of HLA phenotypes. 20 Different ethnicities may exhibit different relations among HLA phenotypes and arterial blood pressure.
Left ventricular hypertrophy (LVH) is causally related to high blood pressure and represents hypertensive target organ damage. 21, 22 However, a dissociation between LVH and blood pressure levels has been reported in an experimental study in New Zealand genetically hypertensive rats. 23 On the other hand, HLAs that are expressed on the surface of myocardial cells have been implicated in the pathophysiology of dilated cardiomyopathy. 24 Similarly, HLA DR2 is more prevalent in Japanese with hypertrophic cardiomyopathy. 25 In a recent study, we also reported an association between certain HLA phenotypes and cardiovascular hypertrophy in hypertensive subjects. 13 However, this work was not designed to evaluate the significance of these HLAs in normotensives. Thus, this preliminary study could not clarify whether the detrimental effect of the HLA phenotypes is independent or is expressed only through the presence of the hypertensive stimulus. In the present study, HLA DR11 was associated with LVH but this association was significant only in the hypertensive group III. This phenotype was not related to LVM in normotensives. It seems, therefore, that the association of this HLA with hypertrophy is only revealed in the presence of intense hypertrophic stimulus, such as moderate or severe arterial hypertension. Similarly, HLA DQ7 and DR17 were associated with vascular wall hypertrophy in hypertensives but not in normotensive individuals. Moreover, this association was independent not only of the blood pressure levels, but also of the serum lipid concentrations.
The role of the inflammation of the arterial wall in the process of atherogenesis has gained support during the last few years. An inflammatory response probably follows the initial vascular injury and results in migration and proliferation of smooth muscle cells. These cells infiltrate the area of inflammation to form an intermediate lesion. When these alterations continue, they promote cardiovascular remodelling. 26 The role of inflammatory cytokines in this hypothesis of cardiovascular hypertrophy remains largely unresolved. So far, these cytokines have been associated with ischaemic and idiopathic dilated cardiomyopathy. They may exert long-term effects on the remodelling of myocardial tissue and they are considered to participate in the process of chronic heart failure. 27 It is unclear why the same HLA phenotypes are more prevalent in normotensives and yet are related to cardiovascular hypertrophy only in hypertensives. The association of the certain HLA phenotypes with hypertensive target organ damage might be related to increased morbidity and mortality of the hypertensive population carrying these HLA antigens. In the evolution of a population during an extended period of time, the aforementioned relation could be translated to a gradual extinction of these hypertensives. The hypothesis that hypertensives with these HLA phenotypes are at a survival disadvantage because of progression of target organ damage is tempting but in fact cannot be supported by such a small number case control study. In addition, it should be noted that hypertension and LVH are late onset disorders and as such do not have a great impact on procreation. On the other hand, the fact that these HLA antigens are implicated only in hypertensives may be because of normotensives not carrying additional genetic/environmental factors required to produce these complex traits.
In conclusion, certain HLA phenotypes may exhibit an association with the levels of arterial blood pressure. Furthermore, these HLA phenotypes may also act as 'promoters' of cardiovascular remodelling when exposed to high levels of blood pressure. However, these findings need replication in a large study before they can be accepted.
